CLINICAL_TRIALS ClinicalTrials.gov record update

A Randomized Phase 1 Trial of Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03199040
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:26:29.805618+00:00
Published At: 2023-12-14T00:00:00+00:00
Record Updated At: 2024-05-28
Results Posted At: 2023-12-14
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Triple Negative Breast Cancer", "Triple Negative Breast Neoplasms", "TNBC - Triple-Negative Breast Cancer", "Triple-negative Breast Carcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2024-05-28"
protocolSection.identificationModule.nctId: "NCT03199040"
protocolSection.identificationModule.officialTitle: "A Randomized Phase 1 Trial of Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2023-12-14"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.